CytomX Therapeutics (NASDAQ:CTMX) Price Target Raised to $17.00 at HC Wainwright

CytomX Therapeutics (NASDAQ:CTMX) had its target price upped by HC Wainwright from $10.00 to $17.00 in a research note issued to investors on Monday morning,Benzinga reports. The brokerage currently has a buy rating on the biotechnology company’s stock.

Several other research analysts have also recently issued reports on CTMX. Piper Sandler lifted their target price on shares of CytomX Therapeutics from $6.50 to $10.00 and gave the stock an “overweight” rating in a report on Tuesday, January 20th. Barclays raised their price target on shares of CytomX Therapeutics from $8.00 to $10.00 and gave the company an “overweight” rating in a research report on Wednesday, February 4th. Cantor Fitzgerald boosted their price objective on shares of CytomX Therapeutics from $6.00 to $10.00 and gave the stock an “overweight” rating in a report on Wednesday, February 4th. JPMorgan Chase & Co. raised CytomX Therapeutics from a “neutral” rating to an “overweight” rating and upped their price objective for the company from $7.00 to $12.00 in a research report on Monday. Finally, Guggenheim reiterated a “buy” rating and set a $10.00 target price on shares of CytomX Therapeutics in a research note on Monday, March 9th. Eight investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $10.88.

CytomX Therapeutics Price Performance

CTMX opened at $6.75 on Monday. The firm has a market cap of $1.14 billion, a PE ratio of 16.88 and a beta of 2.44. The stock has a 50-day moving average price of $5.24 and a 200-day moving average price of $4.07. CytomX Therapeutics has a 1 year low of $0.40 and a 1 year high of $8.21.

Institutional Trading of CytomX Therapeutics

A number of large investors have recently made changes to their positions in the stock. Wells Fargo & Company MN raised its holdings in shares of CytomX Therapeutics by 83.2% during the fourth quarter. Wells Fargo & Company MN now owns 6,605 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 3,000 shares during the last quarter. Farther Finance Advisors LLC purchased a new stake in CytomX Therapeutics in the third quarter worth approximately $25,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in CytomX Therapeutics in the fourth quarter worth approximately $35,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new stake in CytomX Therapeutics in the 3rd quarter worth approximately $34,000. Finally, May Hill Capital LLC purchased a new stake in CytomX Therapeutics during the 4th quarter valued at $46,000. 67.77% of the stock is currently owned by institutional investors.

Key Stories Impacting CytomX Therapeutics

Here are the key news stories impacting CytomX Therapeutics this week:

• Positive Sentiment: Phase 1 expansion data show solid activity in late‑line colorectal cancer — confirmed response rates of 32% at 10 mg/kg Q3W and 20% at 8.6 mg/kg Q3W, estimated PFS ~7.1 months at the higher dose, and manageable safety with ongoing dose optimization. Management is targeting mid‑year FDA interactions to align on a potential registrational trial. Varsetatug Masetecan Continues to Demonstrate Positive Data
• Positive Sentiment: Analyst upgrades and higher price targets lifted sentiment — HC Wainwright raised its target to $17 (buy) and JPMorgan upgraded CTMX to overweight with a $12 target; Seeking Alpha and Benzinga published bullish takes tying valuation to Varseta‑M’s late‑line mCRC opportunity. These notes reinforced upside expectations. Mid‑Cap CytomX Therapeutics’ Colorectal Cancer Data Fuels Stock Rally
• Neutral Sentiment: Market reaction and high trading volume: CTMX experienced unusually heavy volume and a large pre‑market move as headlines circulated and investors digested the clinical readout plus analyst commentary. That amplifies intraday volatility but is informational rather than fundamental by itself. Why CTMX Stock Is Soaring Pre‑Market
• Negative Sentiment: Proposed $250M underwritten public offering of common stock and pre‑funded warrants — the financing will be dilutive and typically weighs on near‑term per‑share metrics despite extending the cash runway for development. CytomX Announces Proposed Public Offering
• Negative Sentiment: Q4 miss on EPS and revenue — CTMX reported a ($0.22) EPS vs. consensus (~$0.08 loss) and revenue well below estimates, reinforcing near‑term cash burn and highlighting the company remains pre‑commercial. These fundamentals contrast with the positive clinical news. CTMX Reports Q4 Loss, Misses Revenue Estimates

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.